By admin 
The multicenter study, a collaborative effort involving the esteemed Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, alongside 14 other prominent institutions across the United States and Canada, marks a significant stride in precision oncology. Its promising results, which could redefine treatment paradigms for aggressive blood cancers, were published in the prestigious journal Nature Medicine, signaling their profound impact on the scientific and medical communities.
Overcoming a Major Hurdle for CAR-T Therapy in Aggressive Blood Cancers
According to Dr. John F. DiPersio, MD, PhD, the Virginia E. & Sam J. Golman Professor of Medicine at WashU Medicine and the corresponding author of the study, this novel gene-editing technique holds the key to surmounting a formidable obstacle that has historically limited the application and effectiveness of Chimeric Antigen Receptor (CAR)-T cell therapy in specific types of blood cancers. While CAR-T therapy has revolutionized the treatment landscape for certain aggressive B-cell leukemias and lymphomas, delivering unprecedented remission rates, its success has been markedly less pronounced in diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
AML and MDS represent a particularly challenging frontier in hematologic oncology. AML, a rapidly progressing cancer of the blood and bone marrow, is characterized by the uncontrolled proliferation of abnormal myeloid cells (myeloblasts). MDS encompasses a group of disorders where the bone marrow fails to produce sufficient healthy blood cells, often progressing to AML. Both conditions carry a high risk of relapse, and for many patients, allogeneic hematopoietic stem cell transplantation (HSCT) remains the most potent curative option, despite its associated risks. However, even after a successful transplant, the persistence of minimal residual disease (MRD) can lead to recurrence, necessitating further, often less effective, therapeutic interventions.
The inherent difficulty in applying CAR-T therapy effectively to AML and MDS, Dr. DiPersio elucidates, stems from a critical biological conundrum: many of the surface proteins found on AML and MDS cancer cells are also ubiquitously expressed on healthy myeloid cells, including the crucial donor stem cells used in transplantation. If CAR-T cells are engineered to target one of these shared proteins—a strategy known as "on-target, off-tumor" toxicity—they inevitably destroy not only the malignant cells but also the healthy, regenerating blood stem cells from the donor. This indiscriminate assault leads to severe and potentially life-threatening complications, including dangerous systemic inflammatory responses, sucha s cytokine release syndrome, and profound, prolonged bone marrow aplasia. Moreover, this collateral damage paradoxically weakens the cancer treatment itself, as a substantial proportion of the CAR-T cells are diverted to attacking healthy targets, thereby diluting their therapeutic concentration and efficacy against the malignant population.
The foundational concept for circumventing this persistent problem was first articulated by Dr. Miriam Y. Kim, MD, currently an assistant professor of medicine at WashU Medicine. Dr. Kim initiated this groundbreaking research during her postdoctoral fellowship at the University of Pennsylvania and further advanced it within Dr. DiPersio’s laboratory before establishing herself as an independent investigator within the WashU Medicine Division of Oncology. Her clinical practice at Siteman Cancer Center, where she also serves as a research member, provides her with direct insights into the challenges faced by patients with aggressive blood cancers.
Precision Engineering: Removing CD33 From Healthy Stem Cells
The innovative approach tested in the clinical trial focused on a specific protein known as CD33. Patients with AML and MDS received donor stem cells that had been meticulously genetically modified to remove the CD33 protein using advanced CRISPR gene-editing technology. The strategic rationale was to create a population of healthy blood cells that would be inherently invulnerable to any future therapeutic interventions specifically designed to target and eliminate CD33-expressing cells. This "shielding" mechanism would allow clinicians to deploy potent CD33-targeted therapies post-transplant with unprecedented precision, ensuring that only the residual cancer cells, which still express CD33, would be eliminated, while the patient’s newly established, healthy blood system remains intact.
"We are immensely encouraged by the results of this study, which demonstrate that a CD33-deleted stem cell transplant yields outcomes strikingly similar to those observed with standard stem cell transplantation," stated Dr. DiPersio, who also directs WashU Medicine’s Center for Gene and Cellular Immunotherapy. "Looking ahead, we are profoundly hopeful that we will be able to seamlessly combine this sophisticated gene-editing technique with highly effective CD33-targeted immunotherapies, such as next-generation CAR-T cells, thereby dramatically improving the treatment landscape and long-term prognosis for patients afflicted with these very aggressive blood cancers." This vision underscores a paradigm shift in how post-transplant relapse might be managed, moving from broad, often toxic, chemotherapy to highly specific, targeted immunotherapies.
Further bolstering the promise of this strategy, Dr. DiPersio and his collaborators have also reported a compelling single-case study involving a patient diagnosed with high-risk AML. This patient initially underwent a CD33-deleted stem cell transplant. When the cancer, unfortunately, recurred, the patient was subsequently treated with CD33-targeted CAR-T cells, which were uniquely manufactured from T cells provided by the same donor who supplied the original gene-edited stem cells. This innovative "shield and attack" strategy yielded remarkable results: the patient, who presented with one of the most aggressive and refractory forms of AML, achieved a complete remission and has remained cancer-free for over one year following the CAR-T treatment. Crucially, normal blood cell production also returned, and all of the patient’s circulating blood cells were found to lack CD33. This critical finding definitively confirmed that the genetically engineered donor cells had successfully engrafted and robustly established themselves within the bone marrow, providing a fully functional, CD33-negative hematopoietic system. This pivotal case report was published in October 2025 in JCO Precision Oncology, highlighting the long-term vision and ongoing research trajectory of this pioneering work.
CD33: The Ideal Target for Cellular Shielding
The selection of CD33 as the target for this gene-editing strategy was not arbitrary but based on sound biological rationale. CD33 is an attractive target because its expression is restricted exclusively to blood-forming cells, including myeloid progenitors and their progeny, and notably, it is absent from other vital non-hematopoietic tissues throughout the body. Furthermore, compelling evidence suggests that CD33 is not essential for normal blood stem cell function or overall human health. A small percentage of individuals are naturally born without the CD33 protein due to genetic variations, and these individuals do not exhibit any related health problems or hematopoietic deficiencies. This "natural experiment" provides a powerful validation for the safety and viability of genetically removing CD33 from donor stem cells.
The underlying theory is elegant in its simplicity and profound in its implications: following a successful transplant with CD33-deleted stem cells, any cells that continue to express CD33 should, in principle, be primarily malignant cancer cells. This creates a therapeutic window wherein a CD33-targeted CAR-T therapy or another CD33-specific immunotherapy could then be deployed to precisely attack and eliminate these residual cancer cells, while leaving the healthy, donor-derived blood cells, which lack CD33, completely unharmed. This selective targeting holds the potential to significantly reduce the severe systemic toxicities typically associated with conventional post-transplant therapies.
The Clinical Trial: Design, Product, and Funding
The Phase 1/2 multicenter clinical trial was meticulously designed to evaluate the safety and preliminary efficacy of this innovative approach. It enrolled 30 adult patients diagnosed with AML or MDS who were considered at a particularly high risk of relapse, a cohort for whom improved treatment options are desperately needed. Before transplantation, donor stem cells were precisely modified using CRISPR gene editing technology to selectively remove the CD33 gene. This cutting-edge gene-editing tool allows for highly accurate and efficient modification of specific DNA sequences.
The resulting CD33-deleted stem cell product, a novel cellular therapeutic, is officially designated tremtelectogene empogeditemcel, or more simply, trem-cel. This investigational product was developed by Vor Biopharma, a biotechnology company focused on engineered hematopoietic stem cell therapies, which also provided the essential funding for this pivotal study. The collaboration between academic research institutions and industry partners is crucial for translating such complex scientific discoveries into tangible clinical applications.
Testing a CD33-Targeted Cancer Treatment: Gemtuzumab Ozogamicin
To rigorously test whether the gene-edited stem cells could indeed withstand a therapy directed at CD33 without experiencing significant myelosuppression, patients in the trial also received a maintenance treatment after transplantation. The drug chosen for this purpose was gemtuzumab ozogamicin. It is important to note that gemtuzumab ozogamicin is not a CAR-T therapy but rather an antibody-drug conjugate (ADC). This sophisticated engineered antibody specifically recognizes and binds to the CD33 protein on the cell surface and then delivers a potent anti-cancer chemotherapy drug directly into cells expressing that protein. This mechanism allows for highly targeted delivery of cytotoxic agents, minimizing systemic exposure.
Gemtuzumab ozogamicin is already approved by the Food and Drug Administration (FDA) for the treatment of CD33-positive AML and is currently being evaluated in clinical trials for CD33-positive MDS. However, despite its targeted nature, the clinical utility of gemtuzumab ozogamicin has historically been constrained by significant side effects. These include notable liver toxicity and, critically, damage to healthy blood-forming cells, leading to myelosuppression. Patients can develop dangerously low levels of white blood cells (neutropenia), red blood cells (anemia), and platelets (thrombocytopenia), which can increase the risk of infection, bleeding, and fatigue, complicating recovery and limiting its use in many post-transplant settings.
Promising Results: Gene-Edited Cells Successfully Engraft and Protect
The results from the trial were highly encouraging. All 30 patients enrolled achieved successful engraftment by day 28 post-transplant. Engraftment signifies that the transplanted stem cells have successfully migrated to the bone marrow, established themselves, and begun to proliferate and produce healthy new blood cells. Some patients even reached this critical milestone sooner, with platelet production, a key indicator of hematopoietic recovery, returning by day 16 on average. These recovery times were remarkably similar to what is typically observed with standard, unmodified stem cell transplantation, suggesting that the gene-editing process did not impair the fundamental ability of the donor cells to engraft and rebuild the patient’s blood system.
The average overall survival in this high-risk patient cohort participating in the trial was just over 14 months, a figure that provides a baseline for evaluating future efficacy in subsequent trials. Nineteen of the patients received at least one cycle of gemtuzumab ozogamicin as part of a carefully designed dose-escalation protocol, which allowed the researchers to identify a recommended dose for future studies.
Crucially, across the different doses administered, patients who received the trem-cel transplant maintained their blood cell counts remarkably well. This finding is profoundly significant, as it strongly suggests that the gene-edited transplant effectively protected them from the severe and often debilitating drops in white blood cells, red blood cells, and platelets that commonly occur when gemtuzumab ozogamicin is used as maintenance therapy after a conventional, unmodified stem cell transplant. This protective effect is precisely the clinical benefit that the researchers aimed to achieve, validating the core hypothesis of the study.
Side Effects and Future Directions
The side effects experienced by patients during the treatment course were broadly similar to those typically associated with standard stem cell transplantation, indicating that the gene-editing process itself did not introduce novel, unexpected toxicities. These common transplant-related complications included anemia, low platelet counts, fever, various infections, and graft-versus-host disease (GvHD), a serious condition in which the donor’s immune cells recognize the patient’s healthy tissues as foreign and mount an attack.
Sadly, seven patients died during the course of the study. Four of these deaths were attributed to the progression of their underlying cancer, underscoring the aggressive nature of AML and MDS and the advanced stage of disease in many enrolled patients. The remaining three deaths were linked to transplant-related complications, including kidney failure, liver toxicity (which can be a known side effect of conditioning regimens and some post-transplant medications), and sepsis, a life-threatening response to infection. These outcomes, while tragic, are unfortunately within the expected range for patients undergoing such intensive and high-risk therapeutic interventions.
Dr. DiPersio concluded that these compelling findings provide a robust foundation for the development of future, more aggressive and effective treatment strategies. The ultimate goal is to seamlessly pair CD33-deleted stem cell transplantation with next-generation CD33-targeted immunotherapies, such as highly potent CAR-T cells or bispecific antibodies. This innovative combination therapy aims to empower doctors to attack residual cancer cells far more aggressively and effectively after transplant, without the inherent fear of simultaneously destroying the healthy, life-sustaining donor cells that are absolutely critical for rebuilding the patient’s blood system. This represents a significant leap forward in personalized, precision medicine for aggressive blood cancers, offering renewed hope for patients facing these formidable diseases.
This pioneering work was made possible through the generous support and funding provided by Vor Biopharma. It is important to note that several co-authors of the published study were employees of the company at the time the research was conducted, highlighting the integrated nature of this translational effort.
